close

Agreements

1 2 3 202
Number of results: 4033

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2017-03-28 BMS (USA - NY) The Parker Institute for Cancer Immunotherapy (USA - CA) the Cancer Research Institute (CRI) (USA - NY) clinical research Cancer - Oncology Clinical research agreement
2017-03-28 Selvita (Poland) Menarini (Italy) SEL24 licensing Cancer - Oncology Licensing agreement
2017-03-28 RegenXBio (USA - MD) nomination Rare diseases - Genetic diseases Nomination
2017-03-27 Xbrane Biopharma (Sweden) Spherotide production facility in Italy validation of a production plant Technology -Services Validation of a production plant
2017-03-27 Alexion Pharmaceuticals (USA - CT) nomination Rare diseases - Genetic diseases Nomination
2017-03-24 PureTech Health (USA - MA) Novartis (Switzerland) two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway diseases related to immunosenescence licensing Immunological diseases Establishment of a new subsidiary in the EU
2017-03-24 C4 Therapeutics (USA - MA) Calico (USA - CA) small molecule protein degraders as therapeutic agents to remove certain disease-causing proteins diseases of aging, including cancer development commercialisation Cancer - Oncology Development agreement
2017-03-23 ImmunoCellular Therapeutics (USA - CA) Memgen (USA - TX ICT-107, ICT-140 and ISF35 clinical research Cancer - Oncology Clinical research agreement
2017-03-23 Retrophin (USA - CA) nomination Rare diseases Nomination
2017-03-23 Novosanis (Belgium) MDxHealth (Belgium) UrNCollect™ distribution Technology - Services - Diagnostic Distribution agreement
2017-03-22 GSK (UK) Regeneron Pharmaceuticals (USA - NY) UK Biobank (UK) genetic sequence data collaboration Technology - Services Collaboration agreement
2017-03-21 Pierre Fabre (France) H-Immune (France) fully human monoclonal antibody candidates research development Cancer - Oncology R&D agreement
2017-03-21 X-Chem (USA - MA) Ono Pharmaceutical (Japan) small molecules development commercialisation Cancer - Oncology Development agreement
2017-03-21 Partners test now Compound: Disease: Type of agreement: Therapeutic_area:asdsadas Plant acquisition
2017-03-21 MDxHealth (Belgium) Lab21 (UK), part of the Novacyt Group (France) SelectMDx™ for Prostate Cancer test prostate cancer distribution Cancer - Oncology - Diagnostic Distribution agreement
2017-03-21 Argen-X (Belgium - The Netherlands) Broteio Pharma (The Netherlands) antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. autoimmune haemolytic anaemia (AIHA), antibody mediated rejection (AMR) following organ transplantation. development Autoimmune diseases Development agreement
2017-03-21 Piqur Therapeutics (Switzerland) nomination Nomination
2017-03-21 Stimunity (France) Institut Curie (France) Inserm (France) VLP-cGAMP technology licensing R&D Cancer - Oncology Licensing agreement
2017-03-20 BMS (USA - NY) CytomX Therapeutics (USA - CA) probodies for up to six oncology targets including CTLA-4 licensing development Cancer - Oncology Development agreement
2017-03-20 X-Chem (USA - MA) Astellas Pharma (Japan) research collaboration Collaboration agreement